Yili Chuanning Biotechnology Co.,Ltd. (SHE:301301)

China flag China · Delayed Price · Currency is CNY
9.58
-0.09 (-0.91%)
At close: Apr 28, 2026
-21.82%
Market Cap 21.74B
Revenue (ttm) 4.41B
Net Income (ttm) 591.52M
Shares Out 2.23B
EPS (ttm) 0.26
PE Ratio 37.27
Forward PE 21.20
Dividend 0.17 (1.76%)
Ex-Dividend Date Apr 29, 2026
Volume 9,851,760
Average Volume 15,005,254
Open 9.83
Previous Close 9.67
Day's Range 9.68 - 9.91
52-Week Range 9.58 - 14.74
Beta 0.26
RSI 34.28
Earnings Date Mar 31, 2026

About SHE:301301

Yili Chuanning Biotechnology Co.,Ltd., together with its subsidiaries, engages in the research, development, and industrialization of bio-fermentation technology and synthetic biology products in China and internationally. It offers antibiotic intermediates comprising erythromycin thiofluorate; cephalosporin intermediates consisting of 7-aminocephalosporanic acid (7-ACA), 7-amino-3-deacetoxycephalosporinic acid (7-ADCA), and D-7ACA; penicillin intermediates, such as 6-aminopenicillanic acid (6-APA) and penicillin G potassium salt; ursodeoxychol... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2010
Employees 3,126
Stock Exchange Shenzhen Stock Exchange
Ticker Symbol 301301
Full Company Profile

Financial Performance

In 2025, SHE:301301's revenue was 4.62 billion, a decrease of -19.83% compared to the previous year's 5.76 billion. Earnings were 769.01 million, a decrease of -45.08%.

Financial Statements

News

There is no news available yet.